. Author manuscript; available in PMC: 2014 Feb 5.

Published in final edited form as: Cancer Chemother Pharmacol. 2008 May 22;63(3):517–524. doi: 10.1007/s00280-008-0769-8

Table 2.

Final pharmacokinetic parameters for both the standard and recirculation model

	V_IRINOTECAN (L/m²)	K₁₂ (h⁻¹)	K₂₁ (h⁻¹)	K_el (h⁻¹)	K₁₃ (h⁻¹)	K_el13 (h⁻¹)	V_SN-38 (L/m²)	K₁₄ (h⁻¹)	K_el14 (h⁻¹)	V_APC (L/m²)
Standard model group (n = 10)
Mean	24.70	38.25	6.66	6.27	2.55	123.69	394.39	1.14	0.41	40.68
Median	5.42	19.26	1.08	3.83	0.22	15.16	12.28	0.06	0.36	1.45
SD	42.50	58.87	18.29	8.36	6.82	282.12	1165.40	3.07	0.17	72.38
Range	0.77–133.40	0.36–197.70	0.01–58.71	0.00–26.82	0.01–21.90	0.18–905.17	0.50–3710.00	0.00–9.83	0.19–0.67	0.00–209.80
Recirculation model group (n = 22)
Mean	8.60	6.52	0.55	5.12	0.29	17.30	19.19	0.31	0.44	14.31
Median	8.66	3.22	0.26	4.27	0.11	10.61	8.12	0.08	0.40	4.30
SD	4.60	8.10	0.70	4.45	0.63	25.43	34.40	0.69	0.16	30.76
Range	1.57–16.41	0.03–36.91	0.00–2.77	0.02–19.06	0.00–2.95	0.52–123.20	0.00–164.53	0.00–3.13	0.19–0.84	0.00–146.50

Out of 32 total patients, the standard model was designated as the optimal model for 10 patients and the recirculation model was designated the optimal model for the remaining 22